If one assumes that antigens from myeloma cells are responsible for activation of T cells and the subsequent upregulation of PD1 in tumor-reactive CD8+ T cells, there should be either more PD1+ cells or higher levels of PD1 on the CD8+ T cells from myeloma patients compared to healthy controls. The gene discussed is CD8A; the disease is neoplasm.